Neurocrine biosciences reports second quarter 2024 financial results and raises 2024 ingrezza sales guidance

Ingrezza® (valbenazine) second quarter net product sales of $580 million representing 32% year-over-year growth ingrezza ® (valbenazine) 2024 net product sales guidance raised to $2.25 - $2.3 billion top-line phase 2 data readouts for nbi-'568 and luvadaxistat remain on track in q3 san diego , aug. 1, 2024 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced its financial results for the second quarter ended june 30, 2024 and provided an update on its 2024 financial guidance. "at neurocrine, we are energized by the tremendous opportunity we see to help many more patients, and we are encouraged by our recent progress, including ingrezza's continued success in treating tardive dyskinesia and huntington's disease chorea and the fda's decision to grant priority review for crinecerfont to treat congenital adrenal hyperplasia," said kevin gorman, ph.d.
NBIX Ratings Summary
NBIX Quant Ranking